Lyn Baranowski - 25 May 2022 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Director
Issuer ticker: RANI
Reported as of: 25 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 May 2022, 08:30:14 UTC
Prior SEC filing: 12 Nov 2021
Next SEC filing: 29 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Svai Sanford, Attorney-in-Fact for Lyn Baranowski

Key filing fact

Lyn Baranowski filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 27 May 2022.

Key facts

This page summarizes Lyn Baranowski's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 May 2022, 08:30.

Change

Previous filing in this sequence was filed on 12 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,240
Change %
Price: $0.000000
Shares after: 22,240
Date: 25 May 2022
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 22,240
Exercise price: $10.89
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).